ALX Oncology (ALXO) Competitors $0.55 +0.01 (+2.75%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$0.55 +0.00 (+0.46%) As of 06/11/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO vs. PLX, CABA, THTX, CCCC, CRDL, CRBU, ATOS, EXOZ, IVVD, and CTNMShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Protalix BioTherapeutics (PLX), Cabaletta Bio (CABA), Theratechnologies (THTX), C4 Therapeutics (CCCC), Cardiol Therapeutics (CRDL), Caribou Biosciences (CRBU), Atossa Therapeutics (ATOS), Exozymes (EXOZ), Invivyd (IVVD), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Its Competitors Protalix BioTherapeutics Cabaletta Bio Theratechnologies C4 Therapeutics Cardiol Therapeutics Caribou Biosciences Atossa Therapeutics Exozymes Invivyd Contineum Therapeutics ALX Oncology (NASDAQ:ALXO) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Which has stronger earnings & valuation, ALXO or PLX? Protalix BioTherapeutics has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$160.80M-$2.47-0.22Protalix BioTherapeutics$59.76M2.09$8.31M$0.0439.25 Do analysts rate ALXO or PLX? ALX Oncology presently has a consensus price target of $3.30, indicating a potential upside of 501.64%. Protalix BioTherapeutics has a consensus price target of $15.00, indicating a potential upside of 855.41%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ALXO or PLX? In the previous week, ALX Oncology had 6 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for ALX Oncology and 0 mentions for Protalix BioTherapeutics. ALX Oncology's average media sentiment score of 0.84 beat Protalix BioTherapeutics' score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media. Company Overall Sentiment ALX Oncology Positive Protalix BioTherapeutics Neutral Which has more volatility and risk, ALXO or PLX? ALX Oncology has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.21, indicating that its share price is 121% less volatile than the S&P 500. Does the MarketBeat Community believe in ALXO or PLX? ALX Oncology received 44 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 81.25% of users gave Protalix BioTherapeutics an outperform vote while only 64.77% of users gave ALX Oncology an outperform vote. CompanyUnderperformOutperformALX OncologyOutperform Votes5764.77% Underperform Votes3135.23% Protalix BioTherapeuticsOutperform Votes1381.25% Underperform Votes318.75% Do institutionals & insiders hold more shares of ALXO or PLX? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 33.4% of ALX Oncology shares are held by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ALXO or PLX more profitable? ALX Oncology has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -93.02% -70.67% Protalix BioTherapeutics -21.03%-30.89%-11.74% SummaryALX Oncology beats Protalix BioTherapeutics on 9 of the 17 factors compared between the two stocks. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.29M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-0.188.7827.1720.06Price / SalesN/A255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book0.146.557.064.70Net Income-$160.80M$143.93M$3.23B$247.88M7 Day Performance4.48%3.97%2.89%2.66%1 Month Performance26.03%11.32%9.06%6.40%1 Year Performance-93.57%4.20%31.40%14.07% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology2.681 of 5 stars$0.55+2.8%$3.30+501.6%-93.6%$29.29MN/A-0.1840News CoverageAnalyst RevisionGap UpPLXProtalix BioTherapeutics2.6134 of 5 stars$1.54-2.5%$15.00+874.0%+31.9%$122.60M$59.76M-11.85200CABACabaletta Bio2.9066 of 5 stars$2.37-4.4%$20.33+757.9%-84.2%$120.26MN/A-1.1050Trending NewsAnalyst ForecastAnalyst RevisionGap DownTHTXTheratechnologiesN/A$2.60+0.8%N/A+107.3%$119.55M$88.67M-26.00140Positive NewsCCCCC4 Therapeutics2.1871 of 5 stars$1.68-2.9%$12.00+614.3%-68.7%$119.29M$39.78M-0.99150Positive NewsCRDLCardiol Therapeutics2.1282 of 5 stars$1.44+2.1%$8.67+501.9%-51.0%$118.96MN/A-3.6920CRBUCaribou Biosciences3.0502 of 5 stars$1.27+0.8%$8.50+569.3%-39.2%$118.12M$9.92M-0.77100Analyst RevisionATOSAtossa Therapeutics1.648 of 5 stars$0.91+1.6%$6.17+574.6%-29.2%$118.07MN/A-4.168EXOZExozymesN/A$13.96+3.9%N/AN/A$116.82MN/A0.0029News CoverageIVVDInvivyd3.8114 of 5 stars$0.97-2.1%$5.85+504.2%-46.4%$116.15M$36.69M-0.49100Positive NewsCTNMContineum Therapeutics2.568 of 5 stars$4.48-5.7%$22.50+402.2%-71.3%$115.91M$50M-2.2731 Related Companies and Tools Related Companies Protalix BioTherapeutics Competitors Cabaletta Bio Competitors Theratechnologies Competitors C4 Therapeutics Competitors Cardiol Therapeutics Competitors Caribou Biosciences Competitors Atossa Therapeutics Competitors Exozymes Competitors Invivyd Competitors Contineum Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALXO) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
